The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 16.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 19% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. Since the last review it entered the Tech 100.
Lam Research
LRCX · a US exchange · USD · Market cap $318.3B · 20,600 employees
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits in the United States, China, Korea, Taiwan, Japan, Sout…
PASS · Titan Ethical · score 77.5Price as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 16:51 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price230.72 USD at the 3 Nov 2026 close
- Our value readFair vs our fair value, as of 3 Nov 2026
- Our regime readDistribution, as of 3 Nov 2026
- Ethical screenPasses, score 77.5 out of 100
- OptionsOpen interest leans slightly to calls (put/call 0.94)
- Last reviewed3 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $227.60 to $261.74, base estimate $227.60 (screen dated 2026-11-03).
- Trend Distribution
- Insiders insiders sold, $7,128,428, latest filing 2026-10-23
- Positioning political buying, disclosed 2026-10-15
- Options put/call open interest 0.94, read 2026-11-03
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Lam Research holds its Distribution at $230.72. Consolidating, no directional conviction, held for 45 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 45 days |
| Price at the screen | $230.72 |
| Valuation | 37.91 trailing · 20.93 forward price to earnings |
| Values screen | PASS · score 77.5 |
| Beta | 1.85 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 21.01% | Below 33% | Interest-bearing debt is just 21.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 45.77% | Below 49% | Money owed to the company is 45.8% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.25% | Below 5% | Only 1.3% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Lam Research clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 21%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LRCX's ethical verdict changes
Today LRCX passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 3 Nov 2026: it trades above our $227.60 fair value estimate, strong competitive moat, 54.40% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. The price runs 1.4% above the base estimate.
Third-party analyst targets: 30 covering, consensus Strong Buy. The average target sits +53% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $227.60, with a range of $227.60 to $261.74, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a strong moat and 32% profit margins. At the screened price it sits 1% above our $227.60 fair value: priced for the quality, not a bargain.
| Forward P/E | 20.9xcheap for a company growing this fast |
| Trailing P/E | 37.9xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 6.71 |
| EPS, forward | 12.15 |
| Revenue growth | +54.4%growing very fast |
| Profit margin | 32.3%highly profitable on every dollar of sales |
| Return on equity | 70.1%an exceptional return on shareholder capital |
| FCF yield | 1.43% |
| Dividend yield | 0.35% |
| Debt to equity | 0.27minimal debt: a conservative balance sheet |
| Current ratio | 2.48comfortably covers its short-term bills |
| Beta | 1.85much more volatile than the market |
| Short interest, float | 0.02% |
| 52-week range | 135.50 - 438.50 |
| Moat | STRONG |
| Market cap | $318.3B |
| Employees | 20,600 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeLRCX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 19% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 6% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 6% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 6% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 70% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 70% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 70% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 70% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 70% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 257%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (32 analysts) rates it buy, with a mean price target of $312. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Elon Musk’s Tesla and SpaceX protest NYSE parent's new plan Yahoo Finance · 19h ago
- Tesla, Amazon, and SpaceX among companies snubbing tokenized stocks Yahoo Finance · 20h ago
- Lam Research Lost 34% in a Month. Bernstein Sees 53% Upside From Here Yahoo Finance · 21h ago
- Applied Materials Just Dropped 29% In a Month: Will November 12 Earnings Rescue or Break AMAT Stock? Yahoo Finance · 21h ago
- Lam Research Sees Strong 2027 Growth as Shareholders Back Board, Pay Plan Yahoo Finance · 22h ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Archer Timothy | Pres, CEO | S - Sale+OE | 31,400 | $7,128,428 |
| 2026-05-01 | Fernandes Neil J | SVP | Sale | 18,170 | $4,635,894 |
| 2026-04-27 | Harter Ava | GC | Sale | 6,010 | $1,554,547 |
| 2026-03-04 | Bettinger Douglas R | CFO, EVP | Sale | 50,057 | $11,214,270 |
| 2026-03-04 | Harter Ava | GC | Sale | 1,500 | $333,990 |
| 2026-03-02 | Bettinger Douglas R | CFO, EVP | Sale | 40,329 | $9,284,542 |
| 2026-03-02 | Harter Ava | GC | Sale | 4,000 | $930,000 |
| 2026-02-06 | Brandt Eric | Dir | Sale | 35,000 | $7,896,150 |
| 2025-12-17 | Archer Timothy | Pres, CEO | Sale | 163,300 | $26,758,338 |
| 2025-11-14 | Bettinger Douglas R | CFO, EVP | Sale | 40,080 | $6,036,048 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| 2026-08-13 | Sheldon Whitehouse | Democrat | sell | 1K–15K |
| 2026-08-13 | Sheldon Whitehouse | Democrat | sell | 1K–15K |
| 2026-08-13 | Sheldon Whitehouse | Democrat | sell | 1K–15K |
| 2026-08-13 | Sheldon Whitehouse | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $296.05 | +9.0% | · | $1,090 | +9.0% |
| 2 months | $263.66 | +22.4% | · | $1,224 | +22.4% |
| 3 months | $209.49 | +54.0% | · | $1,540 | +54.0% |
| 6 months | $168.51 | +91.5% | $0.26 | $1,916 | +91.6% |
| 1 year | $90.34 | +257.2% | $1.01 | $3,583 | +258.3% |
| 2 years | $98.49 | +227.6% | $1.90 | $3,295 | +229.5% |
| 3 years | $58.93 | +447.5% | $2.67 | $5,521 | +452.1% |
| 5 years | $60.88 | +430.0% | $3.92 | $5,365 | +436.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever LRCX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.